Skip to main content
Home > Week in Review > Deals

Chronological Index of : Deals

 Current Issue
  • Aerocrine, Circassia deal

    Aerocrine AB, Solna, Sweden Circassia Pharmaceuticals plc (LSE:CIR), Oxford, U.K. Business: Inflammation Circassia completed its acquisition of Aerocrine for SEK2.55 per share (see BioCentury, June 15).

    Published on 6/22/2015
  • Almac, Genentech, Roche deal

    Almac Group Ltd., Craigavon, U.K. Genentech Inc., South San Francisco, Calif. Roche (SIX:ROG;OTCQX:RHHBY), Basel, Switzerland Business: Cancer Almacs Almac Discovery oncology subsidiary granted Roches Genentech unit …

    Published on 6/22/2015
  • arGEN-X, Leo Pharma deal

    arGEN-X N.V. (Euronext:ARGX), Breda, the Netherlands Leo Pharma A/S, Ballerup, Denmark Business: Dermatology, Inflammation arGEN-X granted Leo exclusive, worldwide rights to develop and commercialize ARGX-112, a …

    Published on 6/22/2015
  • Besins Healthcare, Atossa Genetics deal

    Besins Healthcare S.A., Bangkok, Thailand Atossa Genetics Inc. (NASDAQ:ATOS), Seattle, Wash. Business: Cancer Besins granted Atossa exclusive, worldwide rights to develop and commercialize afimoxifene gel to treat and …

    Published on 6/22/2015
  • Boehringer Ingelheim, Eureka Therapeutics deal

    Boehringer Ingelheim GmbH, Ingelheim, Germany Eureka Therapeutics Inc., Emeryville, Calif. Business: Cancer, Antibodies Boehringer Ingelheim partnered with Eureka Therapeutics to discover antibodies to treat cancer. …

    Published on 6/22/2015
  • Cynvenio Biosystems, Livzon deal

    Cynvenio Biosystems Inc., Westlake Village, Calif. Livzon Pharmaceutical Group Inc. (SZSE:000513;HKSE:1513), Zhuhai, China Business: Diagnostic Cynvenio formed a 50/50 China-based JV with Livzon to develop and market …

    Published on 6/22/2015
  • Cypher Genomics, Celgene deal

    Cypher Genomics Inc., San Diego, Calif. Celgene Corp. (NASDAQ:CELG), Summit, N.J. Business: Pharmacogenetics The companies will use Cyphers Coral technology to discover biomarkers that correlate patient response to drug…

    Published on 6/22/2015
  • Diaxonhit, Felicitex Therapeutics deal

    Diaxonhit (Euronext:ALEHT), Paris, France Felicitex Therapeutics Inc., Cambridge, Mass. Business: Cancer Diaxonhit granted Felicitex exclusive, worldwide rights to develop and commercialize preclinical small molecule …

    Published on 6/22/2015
  • Epirus, Chemo Group deal

    Epirus Biopharmaceuticals Inc. (NASDAQ:EPRS), Boston, Mass. Chemo Group, Barcelona, Spain Business: Autoimmune, Biosimilars Epirus granted Chemos mAbxience subsidiary rights to commercialize BOW015 in Argentina, Chile, …

    Published on 6/22/2015
  • Forma Therapeutics, Boehringer Ingelheim deal

    Forma Therapeutics Inc., Watertown, Mass. Boehringer Ingelheim GmbH, Ingelheim, Germany Business: Cancer Forma received undisclosed milestone payments from Boehringer under a 2012 deal to develop and discover small …

    Published on 6/22/2015
  • Forma Therapeutics, Celgene deal

    Forma Therapeutics Inc., Watertown, Mass. Celgene Corp. (NASDAQ:CELG), Summit, N.J. Business: Cancer Forma received an undisclosed milestone payment from Celgene under a 2014 deal to discover and develop compounds …

    Published on 6/22/2015
  • Human Longevity, Cleveland Clinic deal

    Human Longevity Inc., San Diego, Calif. Cleveland Clinic, Cleveland, Ohio Business: Cardiovascular Human Longevity and the Cleveland Clinic partnered to identify genes and pathways associated with cardiovascular disease…

    Published on 6/22/2015
  • Kythera, Allergan deal

    Kythera Biopharmaceuticals Inc. (NASDAQ:KYTH), Calabasas, Calif. Allergan plc (NYSE:AGN), Dublin, Ireland Business: Dermatology Allergan will acquire Kythera for about $2.1 billion in a cash and stock deal. Kythera …

    Published on 6/22/2015
  • Memorial Sloan Kettering, Atara Biotherapeutics deal

    Memorial Sloan Kettering Cancer Center, New York, N.Y. Atara Biotherapeutics Inc. (NASDAQ:ATRA), Brisbane, Calif. Business: Infectious, Cancer Atara exercised its option to license exclusive, worldwide rights to develop…

    Published on 6/22/2015
  • Nektar, University of Texas MD Anderson Cancer Center deal

    Nektar Therapeutics (NASDAQ:NKTR), San Francisco, Calif. University of Texas MD Anderson Cancer Center, Houston, Texas Business: Cancer Nektar and MD Anderson partnered to conduct a Phase I/II trial to evaluate NKTR-214…

    Published on 6/22/2015
  • PatientsLikeMe, FDA deal

    PatientsLikeMe Inc., Cambridge, Mass. U.S. Food and Drug Administration (FDA), Silver Spring, Md. Business: Pharmaceuticals PatientsLikeMe granted FDA access to the companys patient-reported data, which the agency said …

    Published on 6/22/2015
  • Prosonix, Circassia deal

    Prosonix Ltd., Oxford, U.K. Circassia Pharmaceuticals plc (LSE:CIR), Oxford, U.K. Business: Pulmonary, Generics, Inflammation Circassia completed its acquisition of Prosonix (see BioCentury, June 15).

    Published on 6/22/2015
  • Pulmatrix, Ruthigen deal

    Pulmatrix Inc. (NASDAQ:PULM), Lexington, Mass. Ruthigen Inc., Santa Rosa, Calif. Business: Pulmonary, Drug delivery Pulmatrix completed its reverse merger with Ruthigen (see BioCentury, April 13).

    Published on 6/22/2015
  • R-Tech Ueno Ltd, Hokkaido University deal

    R-Tech Ueno Ltd. (JASDAQ:4573), Tokyo, Japan Hokkaido University, Sapporo, Japan Business: Ophthalmic R-Tech partnered with the university to develop R-Techs RTU-1096. The biotech will provide the compound to Hokkaido, …

    Published on 6/22/2015
  • Rani Therapeutics, Novartis deal

    Rani Therapeutics LLC, San Jose, Calif. Novartis AG (NYSE:NVS;SIX:NOVN), Basel, Switzerland Business: Drug delivery The companies partnered to evaluate delivering Novartis biologics using Ranis oral drug delivery …

    Published on 6/22/2015
  • Sorrento, NantWorks deal

    Sorrento Therapeutics Inc. (NASDAQ:SRNE), San Diego, Calif. NantWorks LLC, Los Angeles, Calif. Business: Cancer NantWorks will acquire the Igdrasol Inc. subsidiary of Sorrento for $90 million up front and up to $1.2 …

    Published on 6/22/2015
  • Stanford University, Pieris Pharmaceuticals deal

    Stanford University, Stanford, Calif. Pieris Pharmaceuticals Inc. (OTCQB:PIRS), Freising-Weihenstephan, Germany Business: Cancer Pieris gained access to laboratory resources at the university, including translational …

    Published on 6/22/2015
  • Taiho, Servier deal

    Taiho Pharmaceutical Co. Ltd., Tokyo, Japan Servier, Neuilly-sur-Seine, France Business: Cancer Taiho granted Servier exclusive rights to develop and commercialize TAS-102 in Europe and undisclosed countries. Taiho …

    Published on 6/22/2015
  • Abbott, AstraZeneca deal

    Abbott Laboratories (NYSE:ABT), Abbott Park, Ill. AstraZeneca plc (LSE:AZN;NYSE:AZN), London, U.K. Business: Diagnostic, Inflammation Abbott and AstraZeneca partnered to develop and commercialize companion diagnostics …

    Published on 6/15/2015
  • Abeona, PlasmaTech Biopharmaceuticals deal

    Abeona Therapeutics LLC, Cleveland, Ohio PlasmaTech Biopharmaceuticals Inc. (NASDAQ:PTBI), Dallas, Texas Business: Endocrine/Metabolic PlasmaTech acquired Abeona for 4 million PlasmaTech shares, or about $31.9 million …

    Published on 6/15/2015

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993